Case Western Reserve University researcher Farren Briggs was awarded $1.2 million over three years from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health to identify biomarkers to improve the diagnoses of multiple sclerosis (MS), including the ability to monitor disease activity and progression.

Briggs, the principal investigator, will work in collaboration with colleagues at the Mayo Clinic and Duke University.

It is possible that nearly 20% of the 900,00 people in the U.S. with an MS diagnosis may have been misdiagnosed. The psychological, physical, financial and ethical costs of misdiagnosis are high. Not only does the underlying disease go untreated, but MS therapies have common side effects and can cause harm in those with other demyelinating disorders, so it is important to improve specificity in diagnosing MS.”

Farren Briggs, Assistant Professor, Department of Population and Quantitative Health Sciences in the School of Medicine

MS is a chronic and progressive autoimmune disease that attacks the protective sheath covering the nerve cells in the brain and spinal cord. MS symptoms are highly variable and can include impaired muscular coordination, numbness, tremors, and severe fatigue, as well as impaired speech and blurred vision. Most people with MS experience phases when the disease seems stable or with improved symptoms that can last months or years. They can then unpredictably experience relapses with new or worsening symptoms.

Unfortunately, most available MS therapies only modify the inflammation that causes relapses. But these therapies have limited effect on the neurodegeneration that causes symptoms to get more severe. A challenge for drug development is the absence of reliable biomarkers that signal the onset of relapse or changes in the disease’s progression.

To address the challenge posed by initial misdiagnosis, Briggs and his colleagues will identify blood serum biomarkers that accurately classify people with MS, compared to unaffected individuals and those with other rare demyelinating and inflammatory diseases.

The team also will compare people with MS who experience relapses to those who are not, and will also compare benign and progressive MS. The goal is to identify biomarkers that can help monitor MS progression, which will contribute to improving clinical trials for new therapeutics to eventually improve treatment.


Case Western Reserve University

Post source: Medical news

The post CWRU researcher receives $1.2 million to identify biomarkers for improving MS diagnoses appeared first on Sound Health and Lasting Wealth.

No related posts.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

THCB Gang Episode 58 – Thurs June 17, 1pm PT – 4pm ET

Episode 58 of “The THCB Gang” will be live-streamed on Thursday, June…

Kidney cancer: Night sweats are an early sign of the deadly disease

Kidney, or renal, cancer refers to any cancer that involves the kidney.…

Experts at UVU summit say mental health resources are vitalin education

  Hundreds of participants attended a Mental Health Summit and Suicide Prevention…

The Royal Family’s Mental Health Is as Important as It Is Invisible

Some fans of the British royal family believe that it is a…